Try GOLD - Free
We are expanding our footprint in high-growth markets, particularly in Europe and Asia
Express Pharma
|April 2025
Cotecna Group is a leading provider of testing, inspection, and certification services, providing regulatory compliance solutions across various industries, including pharma. Sebastien Dannaud, Global CEO, Cotecna shares insights on the company's expansion plans, innovation, and growth strategies for the pharma sector, in an exclusive interview with Lakshmipriya Nair
Can you elaborate on the Cotecna Group's offerings and how they support pharma companies in meeting global regulatory standards, especially in highly regulated markets?
At Cotecna, we understand the critical importance of regulatory compliance in the pharma industry, particularly in highly regulated markets such as Europe and Asia. Our expertise spans across Good Manufacturing Practices. (GMP), Good Laboratory Practices (GLP), Good Distribution Practices (GDP), as well as regulatory requirements set by major bodies such as the EMA and WHO.
To support pharma companies in navigating these complex regulations, we offer comprehensive testing and auditing services conducted onsite. Our specialised facilities, such as SHIVA Lab and Cotecna Life Sciences in India, provide advanced pharma testing and regulatory support, ensuring that products meet stringent safety and quality standards. Similarly, Neotron Food Pharma Lab in Europe offers specialised pharma and nutra testing, with a particular focus on biopharma solutions.
By fostering strong synergies between India and Neotron, we ensure a harmonised global service offering that provides consistency, reliability, and compliance assurance to pharma clients worldwide.
How does Cotecna differentiate itself from competitors in the pharma testing and certification space? Are there specific strategies or expansion plans targeting high-growth regions like the US, Europe, and emerging markets?
Cotecna stands out due to its strong technical and scientific expertise, combined with its agility, responsiveness, and commitment to tailored solutions. We often describe our approach as "smart, agile, and highly responsive." This mindset allows us to deliver faster turnaround times, customised services, and a client-centric approach that ensures we meet the specific needs of our partners.
This story is from the April 2025 edition of Express Pharma.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Express Pharma
Express Pharma
Standardisation vs customisation in single-use systems for bioprocessing: What do biopharma companies need?
Priyabrata Pattnaik, CEO, Ami Polymer highlights the balance between standardisation and customisation in single - use systems in biopharma manufacturing
5 mins
May 2026
Express Pharma
Ensuring Pharma compliance with testo data measurement technology
Due to the crucial necessity and its direct impact on human health and welfare, Pharma is probably the most important and critical sector among others.
3 mins
May 2026
Express Pharma
China+1 moment for pharma: How India can convert opportunity into long-term contracts
Manish Jain, Director, Naprod Life Sciences explains how India must move beyond cost advantage to lead with reliability, quality, and transparency to reshape global pharma supply chains and position itself as a trusted, long-term partner
3 mins
May 2026
Express Pharma
Beyond scale: Rethinking new frontiers in building excellence
At the Injectable Innovations Conclave 2026, hosted by Express Pharma, industry leaders examined the trends, technologies and strategies shaping the next phase of injectable growth, reports
10 mins
May 2026
Express Pharma
Waters receives CE mark for BD BACTEC FXI Culture System under EU IVDR
Next-generation blood culture system records ~3-hour faster detection time and introduces automated blood volume measurement
2 mins
May 2026
Express Pharma
JNPC: Carrying forward a 20-year old legacy
Billed as India's first bulk drug, chemicals and allied manufacturing parks and one of the most successful public-private partnerships (PPP) in the pharma sector, the Jawaharlal Nehru Pharma City (JNPC), also known as Visakha Pharma City, was set up in February 2005 as a PPP initiative by the Govt of Andhra Pradesh (GoAP) through its nodal agency Andhra Pradesh Industrial Infrastructure Corporation (APIIC) with the Ramky Group on a Build-Own-Operate (BOO) basis for 20 years.
3 mins
May 2026
Express Pharma
Romaco's sustainable blister packaging line at interpack
At this year's interpack, the Romaco Group will present its sustainable Unity 600 high-speed blister packaging line, featuring – for the first time – the PF 75 stretch bander.
6 mins
May 2026
Express Pharma
Even drug-resistant cancer targets can be tackled with the right design strategy
Dr Bajarang Kumbhar, Assistant Professor, Sunandan Divatia School of Science, NMIMS Mumbai, explains how Al-driven computational biology is reshaping CAR-T therapy and highlights how these approaches help cut drug discovery timelines and improve targeted, personalised cancer treatment, in an interaction with Kalyani Sharma
7 mins
May 2026
Express Pharma
Navigating legal and regulatory landscape of GLP-1 drugs in India
GLP-1 drugs are drawing sharp regulatory and legal scrutiny, especially with generics entering post-patent expiry. They emphasise that navigating IP, compliance, and marketing rules is now critical for stakeholders
5 mins
May 2026
Express Pharma
From back office to brain trust: How life sciences GCCs are redefining leadership hiring in India
Sai Gandhi, Partner, Positive Moves points out that life sciences GCCs in India are moving from support roles to driving core innovation and global strategy. In turn, leadership hiring is shifting toward cross-functional, globally savvy leaders who can deliver enterprise-wide impact
4 mins
May 2026
Listen
Translate
Change font size

